Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review). 2010

Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
Department of Hematology, Emergency Universitary Hospital Bucharest, 050098 Bucharest, Romania. anamariavladareanu@yahoo.com

The Philadelphia negative chronic myeloproliferative neoplasms are hematological disorders with several diagnostic challenges. Due to recent molecular findings, the WHO classification of Tumors of Hematopoietic and Lymphoid Tissue 2008 reorganized the field of chronic myeloproliferative diseases. Thus, specific molecular markers provide important information for current diagnostic strategies. This review highlights the important diagnostic tools in classical and atypical myeloproliferative neoplasms mainly the JAK2V617F mutation, the Mpl receptor, Polycythemia rubra vera 1 (PRV1), platelet-derived growth-factor receptor alpha (PDGFRA), platelet-derived growth-factor receptor beta (PDGFRB), fibroblast growth-factor receptor 1 (FGFR1) and c-kit tyrosine kinase. A description of the origin, clinical correlations and role in diagnosis and therapy is provided for each of these molecular markers.

UI MeSH Term Description Entries
D007519 Isoantigens Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS. Alloantigens,Alloantigen,Isoantigen
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009196 Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. Disorder, Myeloproliferative,Disorders, Myeloproliferative,Myeloproliferative Disorder
D010677 Philadelphia Chromosome An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE). Ph1 Chromosome,Ph 1 Chromosome,1 Chromosomes, Ph,Chromosome, Ph 1,Chromosome, Ph1,Chromosome, Philadelphia,Chromosomes, Ph 1,Chromosomes, Ph1,Ph 1 Chromosomes,Ph1 Chromosomes
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D051496 Receptor, Fibroblast Growth Factor, Type 1 A fibroblast growth factor receptor with specificity for FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCAN; and NEURONAL CELL ADHESION MOLECULES. Several variants of the receptor exist due to multiple ALTERNATIVE SPLICING of its mRNA. Fibroblast growth factor receptor 1 contains three extracellular IMMUNOGLOBULIN C2-SET DOMAINS and is a tyrosine kinase that transmits signals through the MAP KINASE SIGNALING SYSTEM. Fibroblast Growth Factor Receptor 1,CD331 Antigen,FGFR1 Protein,FGFR1 Tyrosine Kinase,Fibroblast Growth Factor Soluble Receptor 1,fms-Like Tyrosine Kinase-2,Antigen, CD331,fms Like Tyrosine Kinase 2
D053614 Janus Kinase 2 A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS. JAK-2 Protein Tyrosine Kinase,JAK2 Protein Tyrosine Kinase,JAK 2 Protein Tyrosine Kinase
D053628 Receptors, Thrombopoietin Cell surface receptors that are specific for THROMBOPOIETIN. They contain two central FIBRONECTIN TYPE III DOMAINS and signal through interaction with JANUS KINASES such as JANUS KINASE 2. Antigens, CD110,CD110 Antigens,MPL Ligand Receptor,Thrombopoietin Receptor,Thrombopoietin Receptors

Related Publications

Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
June 2004, Pathologie-biologie,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
January 2005, Blood reviews,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
January 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
January 2008, Hematology. American Society of Hematology. Education Program,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
January 2011, Current cancer drug targets,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
September 2007, Current stem cell research & therapy,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
December 1998, Mayo Clinic proceedings,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
August 2009, American journal of clinical pathology,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
December 2021, Journal of clinical medicine,
Ana Maria Vladareanu, and Carsten Müller-Tidow, and Horia Bumbea, and Sinziana Radesi
August 2002, International journal of hematology,
Copied contents to your clipboard!